<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Reddy, Vivek Y.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">LEADLESS II</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-11-09 11:22:16</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-8</style></pages><abstract><style  face="normal" font="default" size="100%">In the LEADLESS II trial, a leadless cardiac pacemaker was demonstrated to be safe and effective. At 6 months, the serious device-related adverse events occurred in 5.7% of patients, and the primary efficacy end point of acceptable pacing capture threshold and therapeutically acceptable sensing amplitude was achieved in 90% of patients.</style></abstract><number><style face="normal" font="default" size="100%">28 suppl 2</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>